Symposia: Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, real-world evidence
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research, real-world evidence
Monday, December 11, 2023: 4:30 PM-6:00 PM
San Diego Ballroom AB
(Marriott Marquis San Diego Marina)
Moderators:
Irum Khan, MD, Northwestern
and
Christoph Röllig, MD, MSc, Medizinische Klinik und Poliklinik I, Universitätsklinikum TU Dresden
Disclosures:
Röllig: Servier: Consultancy, Honoraria; BMS: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding.
Data on intensive induction chemotherapy regimens for patients with acute myeloid leukemia will be presented, with a focus on the addition of venetoclax to many of the backbone therapies. Addition of a novel FLT3 inhibitor to backbone intensive chemotherapy will also be highlighted.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH